评估多排CT对局部晚期乳腺癌患者局部区域分期的价值
前瞻性单中心研究纳入111例新诊断乳腺癌女性,比较俯卧位专用装置下行胸部增强多排CT与乳腺MRI对局部区域分期的一致性及可靠性,并与54例直接手术者的病理分期对照。结果显示MDCT与MRI在肿瘤大小、多灶性方面一致性高,MRI判断主瘤大小与病理更可靠,而MDCT判断转移淋巴结数目与病理更可靠。
要点
- MDCT与MRI测量肿瘤大小一致性高(ICC 0.91),仅1个(0.1%)肿瘤在MDCT不可见。
- MDCT检出额外恶性病灶敏感度90%、阳性预测值69.2%,但MRI检出更多可疑病灶。
- 直接手术者中,主瘤大小MRI与病理一致性(ICC 0.74)高于MDCT(ICC 0.53);转移淋巴结数目MDCT(ICC 0.69)高于MRI(ICC 0.56)。
核心结论
- 采用专用乳腺协议的胸部增强MDCT在新诊断乳腺癌局部区域分期中与乳腺MRI一致性高、可靠性好。
研究设计与样本
- 前瞻性单中心研究(CAAE: 73328923.1.0000.5432),纳入2019年9月至2021年9月间接受乳腺MRI与胸部增强MDCT分期的乳腺癌参与者111例,MDCT采用俯卧位及类似MRI线圈的定制装置。
关键影像表现/征象
- MRI显示全部原发肿瘤,仅1个(0.1%)肿瘤在MDCT不可见。
- 肿瘤平均大小MRI为3.3 cm ± 2.2,MDCT为3.2 cm ± 2.1(ICC 0.91;95% CI: 0.86, 0.93)。
- 31例参与者两种方法均显示多灶性,1例仅MDCT显示多灶性(一致率99%;κ=0.98;95% CI: 0.94, 1.00)。
- MRI检出更多额外可疑病灶,但MDCT检出几乎所有额外恶性病灶(敏感度90%;阳性预测值69.2%)。
诊断标准与关键数值
- MDCT与MRI肿瘤大小一致性ICC 0.91(95% CI: 0.86, 0.93)。
- 多灶性判断一致率99%,κ=0.98(95% CI: 0.94, 1.00)。
- MDCT检出额外恶性病灶敏感度90%、阳性预测值69.2%。
- 54例直接手术者中,主瘤大小与病理ICC:MRI 0.74(95% CI: 0.59, 0.84)vs MDCT 0.53(95% CI: 0.31, 0.70)。
- 转移淋巴结数目与病理ICC:MDCT 0.69(95% CI: 0.53, 0.81)vs MRI 0.56(95% CI: 0.34, 0.71)。
临床应用与阅片要点
- 采用专用乳腺协议行俯卧位胸部增强MDCT,可获得与乳腺MRI高度一致的肿瘤大小及多灶性信息。
- MDCT判断转移淋巴结数目与病理一致性高于MRI,可辅助腋窝淋巴结评估。
- MRI仍为评估主瘤大小及检出额外可疑病灶的参考,MDCT对额外恶性病灶敏感度90%、阳性预测值69.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To assess the agreement and reliability between multidetector row CT (MDCT) and MRI features for locoregional staging of newly diagnosed breast cancer and to compare these imaging findings with pathologic staging in individuals undergoing upfront surgery. Materials and Methods This prospective single-center study (CAAE: 73328923.1.0000.5432) included participants with breast cancer who underwent breast MRI and contrast-enhanced chest MDCT for staging between September 2019 and September 2021. MDCT was performed in the prone position, using a custom-made device similar to the MRI coil. Agreement between MDCT, MRI, and pathologic results (when available) was expressed as percentages, and reliability was assessed using Fleiss κ and intraclass correlation coefficients (ICCs). Results The study included 111 female participants (mean age ± SD, 48.7 years ± 12.1). MRI depicted all index tumors, and only one (0.1%) was not visible at MDCT. The mean tumor size was 3.3 cm ± 2.2 on MR images and 3.2 cm ± 2.1 on MDCT images (ICC, 0.91; 95% CI: 0.86, 0.93). Multifocality was characterized with both methods in 31 participants and only with MDCT in one participant (agreement, 99%; κ = 0.98; 95% CI: 0.94, 1.00). Although more additional suspicious lesions were detected at MRI, almost all malignant additional lesions (sensitivity, 90%; positive predictive value, 69.2%) were detected at MDCT. In 54 participants who underwent upfront surgery, MRI showed a higher reliability with surgical pathology results for determining the main tumor size (ICC, 0.74; 95% CI: 0.59, 0.84) compared with MDCT (ICC, 0.53; 95% CI: 0.31, 0.70), whereas MDCT was more reliable for determining the number of metastatic nodes (MDCT ICC, 0.69; 95% CI: 0.53, 0.81 vs MRI ICC, 0.56; 95% CI: 0.34, 0.71). Conclusion This study demonstrates that contrast-enhanced MDCT, when performed with a dedicated breast protocol, offers high agreement and reliability with breast MRI for locoregional staging of newly diagnosed breast cancer. Keywords: CT, Breast, Staging Supplemental material is available for this article. © RSNA, 2025.
引用
- Felipe VC, Barbosa PNVP, Chojniak R, et al. Evaluating Multidetector Row CT for Locoregional Staging in Individuals with Locally Advanced Breast Cancer. Radiol Cardiothorac Imaging. 2025. PMID: 40673767. doi:10.1148/ryct.240008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。